{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Avonex%C2%AE+matched+Placebo", "query": { "intervention": "Avonex® matched Placebo" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 8, "total_pages": 1, "next_page_url": null, "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-24T13:43:23.913Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02294058", "title": "Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Sclerosis" ], "interventions": [ { "name": "Ozanimod", "type": "DRUG" }, { "name": "Interferon beta-1a", "type": "DRUG" }, { "name": "Placebo to ozanimod", "type": "DRUG" }, { "name": "Placebo to interferon beta-1a", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 1346, "start_date": "2014-12-03", "completion_date": "2016-12-22", "has_results": true, "last_update_posted_date": "2020-11-25", "last_synced_at": "2026-09-24T13:43:23.913Z", "location_count": 40, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Berkeley, California + 35 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Berkeley", "state": "California" }, { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02294058" }, { "nct_id": "NCT04032158", "title": "Study of Evobrutinib in Participants With Relapsing Multiple Sclerosis (RMS)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Relapsing-remitting Multiple Sclerosis" ], "interventions": [ { "name": "Evobrutinib", "type": "DRUG" }, { "name": "Avonex®", "type": "DRUG" }, { "name": "Avonex® matched Placebo", "type": "DRUG" }, { "name": "Evobrutinib matched Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "EMD Serono Research & Development Institute, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 3, "start_date": "2019-08-26", "completion_date": "2020-04-16", "has_results": true, "last_update_posted_date": "2021-08-05", "last_synced_at": "2026-09-24T13:43:23.913Z", "location_count": 1, "location_summary": "Rockland, Massachusetts", "locations": [ { "city": "Rockland", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04032158" }, { "nct_id": "NCT01247324", "title": "A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Relapsing Multiple Sclerosis" ], "interventions": [ { "name": "Interferon beta-1a", "type": "DRUG" }, { "name": "Ocrelizumab-matching placebo", "type": "DRUG" }, { "name": "Ocrelizumab", "type": "DRUG" }, { "name": "Interferon beta-1a-matching placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 821, "start_date": "2011-08-31", "completion_date": "2022-12-31", "has_results": true, "last_update_posted_date": "2024-03-04", "last_synced_at": "2026-09-24T13:43:23.913Z", "location_count": 40, "location_summary": "Phoenix, Arizona • Carmichael, California • La Jolla, California + 32 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Carmichael", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Laguna Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01247324" }, { "nct_id": "NCT00605215", "title": "BRAVO Study: Laquinimod Double-blind Placebo-controlled Study in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Sclerosis" ], "interventions": [ { "name": "Laquinimod", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Avonex®", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 1331, "start_date": "2008-04-24", "completion_date": "2011-06-10", "has_results": true, "last_update_posted_date": "2022-04-21", "last_synced_at": "2026-09-24T13:43:23.913Z", "location_count": 36, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 31 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00605215" }, { "nct_id": "NCT04032171", "title": "Study of Evobrutinib in Participants With RMS", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Relapsing-remitting Multiple Sclerosis" ], "interventions": [ { "name": "Evobrutinib", "type": "DRUG" }, { "name": "Avonex®", "type": "DRUG" }, { "name": "Avonex® matched Placebo", "type": "DRUG" }, { "name": "Evobrutinib matched Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "EMD Serono Research & Development Institute, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 1, "start_date": "2019-09-10", "completion_date": "2020-05-20", "has_results": true, "last_update_posted_date": "2021-08-05", "last_synced_at": "2026-09-24T13:43:23.913Z", "location_count": 1, "location_summary": "Rockland, Massachusetts", "locations": [ { "city": "Rockland", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04032171" }, { "nct_id": "NCT00436826", "title": "A Phase 2 Study of Cladribine Add-on to Interferon-beta (IFN-beta) Therapy in Multiple Sclerosis (MS) Subjects With Active Disease (ONWARD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Sclerosis" ], "interventions": [ { "name": "Cladribine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Interferon-beta (IFN-beta)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "EMD Serono Research & Development Institute, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 172, "start_date": "2006-11-30", "completion_date": "2012-03-31", "has_results": true, "last_update_posted_date": "2020-10-12", "last_synced_at": "2026-09-24T13:43:23.913Z", "location_count": 21, "location_summary": "Cullman, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 18 more", "locations": [ { "city": "Cullman", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Boulder", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00436826" }, { "nct_id": "NCT00725985", "title": "Oral Cladribine in Early Multiple Sclerosis (MS)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Sclerosis" ], "interventions": [ { "name": "Cladribine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Rebif® new formulation (RNF)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "EMD Serono Research & Development Institute, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 617, "start_date": "2008-12-31", "completion_date": "2012-04-30", "has_results": true, "last_update_posted_date": "2021-03-22", "last_synced_at": "2026-09-24T13:43:23.913Z", "location_count": 24, "location_summary": "Phoenix, Arizona • Newport Beach, California • Denver, Colorado + 21 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Newport Beach", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Fort Collins", "state": "Colorado" }, { "city": "Melbourne", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00725985" }, { "nct_id": "NCT02047734", "title": "Efficacy and Safety Study of Ozanimod in Relapsing Multiple Sclerosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Relapsing Multiple Sclerosis" ], "interventions": [ { "name": "Ozanimod", "type": "DRUG" }, { "name": "Ozanimod placebo", "type": "DRUG" }, { "name": "Interferon beta-1a", "type": "DRUG" }, { "name": "Interferon beta-1a placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 1320, "start_date": "2013-12-03", "completion_date": "2017-04-13", "has_results": true, "last_update_posted_date": "2021-02-11", "last_synced_at": "2026-09-24T13:43:23.913Z", "location_count": 35, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Berkeley, California + 17 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02047734" } ] }